Future Science Group
Download file
Download file
Download file
Download file
Download file
5 files

Cost-effectiveness of pembrolizumab plus chemotherapy as first line treatment in PD-L1-positive metastatic TNBC. Supplementary Tables.

posted on 2022-07-07, 07:52 authored by Joyce O'Shaughnessy, Nicolas Cappoen, Celine Le Bailly De Tilleghem, Zheng-Yi Zhou, Emma Gray, Wilbur James. Pan, Amin Haiderali, Peter Fasching, Min Huang, Mitashri Chaudhuri


Supplementary Table S1. AIC/BIC of parametric function fitting for OS, PFS and ToT


Supplementary Table S2. AE related hospitalization costs (2021 USD)


Supplementary Table S3. Summary of scenario analyses results


Supplementary Table S4. Summary of subgroup analysis results


Supplementary Table S5. Cost-effectiveness results for pembrolizumab plus chemotherapy (weighted average) vs. chemotherapy (weighted average)